What it sells
AI enabling digital urine diagnostics in the home
Business model breakdown
Buyer: who owns the budget?
Insurers/payers reimburse the program; providers (urology and primary care clinics) prescribe it.
Trigger: what makes them buy now?
UnverifiedRecurrent UTI patients and clinics wanting early intervention and fewer repeat visits and antibiotic courses.
Workflow: what inputs become what output?
Patient uses UrinDx at-home device each time they use the bathroom; algorithms track trends; Starling care team triages and escalates to the clinician when symptoms are confirmed.
Economics: what it saves and how it charges
Program is reimbursed by insurance; most patients pay $0 for UrinDx; providers get triage reimbursement. FDA clearance pending.
Distribution: how it reaches customers
Through partnered providers and a patient eligibility check form.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2022 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.